A phase 2a clinical trial of molnupiravir in patients with COVID-19

molnupiravir dose  during treatment with LAGEVRIO and for 4 days after the last dose of LAGEVRIO Talk to your healthcare provider about reliable birth control methods • Before dose of molnupiravir or placebo, and were not hospitalized before the first dose Every effort was made to ascertain survival and

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase I, open-label, dose-escalating, randomized controlled study  Molnupiravir is a prodrug with antiviral activity against SARS-CoV-2 The dosage of molnupiravir is 800 mg, or four of the 200-mg capsules taken

If you cannot swallow capsules whole, consult with a healthcare provider • Molnupiravir can be taken with or without food • What to do if you miss a dose: • Breastfeeding is not recommended during treatment and for 4 days after the last dose of molnupiravir A lactating individual may consider interrupting